Accord Healthcare B V Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Accord Healthcare B V Pharmaceutical Import Records from India — 3 Products, $544.4K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Accord Healthcare B V — Pharmaceutical Importer Profile (2026) | 3 Products, $544.4K Trade | TransData Nexus

Accord Healthcare B V

Pharmaceutical Importer · Netherlands · Oncology Focus · $544.4K Total Trade · DGFT Verified

Accord Healthcare B V is a pharmaceutical importer based in Netherlands with a total trade value of $544.4K across 3 products in 2 therapeutic categories. Based on 22 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Accord Healthcare B V sources from 2 verified Indian suppliers, with Intas Pharmaceuticals Limited accounting for 97.7% of imports.

Accord Healthcare B V — Import Portfolio & Supplier Network

Accord Healthcare B V import network — 3 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Accord Healthcare B V?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$2.9M	144	97.7%
Torrent Pharmaceuticals Limited	$67.9K	2	2.3%

Accord Healthcare B V sources from 2 verified Indian suppliers across .

What Formulations Does Accord Healthcare B V Import?

Formulation	Value	Ships
Naproxen accord 500MG TAB	$100.0K	2
Nuprinaspirin 75MG 2x14t	$92.4K	3
Lisinopril accord 20 MG TAB	$83.4K	2
Capecitabine accord 500 MG	$74.7K	2
Azacitidine pow,100MG/v	$72.1K	2
Lisinopril accord 10 MG TAB	$69.3K	3
Valaciclovir hcl 500MG	$64.9K	2
Clarithromycin500mg	$57.6K	2
Borte rtu2.5MG/ml1.4ml1vaco-pp-dk/no/is	$52.1K	2
Imatinib400mg 3x10t alu	$50.0K	1
Daptomycin powder,350MG/v	$50.0K	1
Daptomycin powder,350MG/v	$50.0K	1
Borte rtu2.5MG/ml1.4ml1vaco-pp-ee/lt/lv	$50.0K	1
Bortezo rtu,2.5MG/ml1.4ml1vaco-pp-fi/se	$50.0K	1
Temozolomide accord 140 MG	$50.0K	1

Accord Healthcare B V imports 126 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 3 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Temozolomide	Advanced Oncology	$250.0K	5	1.1%	13
2	Fluorouracil	Oncology	$167.3K	11	1.4%	15
3	Cisplatin	Oncology	$127.1K	6	1.0%	17

Accord Healthcare B V imports 3 pharmaceutical products across 2 categories into Netherlands totaling $544.4K.

Accord Healthcare B V — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Accord Healthcare B.V., established in 2008, is a pharmaceutical company headquartered at Winthontlaan 200, 3526 KV, Utrecht, Netherlands. (transfirm.nl) As a subsidiary of Intas Pharmaceuticals, Accord Healthcare B.V. specializes in the importation and distribution of generic and specialty pharmaceuticals, focusing on oncology, immunosuppressants, central nervous system (CNS) drugs, cardiovascular and diabetes medications, respiratory treatments, oral gastroenterology, and urology products.

The company's mission is to expand patient access to medicines while providing novel solutions that enhance the pharmaceutical experience for both healthcare providers and patients. (accordhealthcare.us) Accord Healthcare B.V. serves a diverse clientele, including public and private hospital groups, wholesalers, and pharmacies, ensuring a broad distribution network across the Netherlands.

2Distribution Network

Accord Healthcare B.V. operates from its central office in Utrecht, Netherlands. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive product portfolio and partnerships with various healthcare entities suggest a well-established distribution network. This network likely encompasses key regions within the Netherlands, ensuring efficient delivery of pharmaceutical products to hospitals, wholesalers, and pharmacies.

3Industry Role

In the Netherlands' pharmaceutical supply chain, Accord Healthcare B.V. functions primarily as a pharmaceutical importer and distributor. By sourcing generic and specialty medicines from manufacturers, including those in India, the company plays a crucial role in making these products accessible to Dutch healthcare providers and patients. This position enables Accord Healthcare B.V. to contribute significantly to the availability of essential medications within the Dutch market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Accord Healthcare B V

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Accord Healthcare B.V. demonstrates a high degree of supplier concentration, with 97.7% of its imports from India sourced from Intas Pharmaceuticals Limited. This suggests a strategic partnership, potentially offering benefits such as favorable pricing, consistent product quality, and reliable supply chains. However, this concentration also introduces risks associated with dependency on a single supplier, including potential disruptions due to regulatory changes, production issues, or geopolitical factors. The limited number of shipments from Torrent Pharmaceuticals Limited indicates a less stable or less significant relationship, which may not provide the same level of security.

2Supply Chain Resilience

The resilience of Accord Healthcare B.V.'s Indian supply chain appears to be moderate. The company's reliance on a single supplier, Intas Pharmaceuticals Limited, for the majority of its imports could pose challenges in the event of supply disruptions. The limited engagement with other suppliers, such as Torrent Pharmaceuticals Limited, suggests a lack of diversified sourcing strategies. Additionally, the absence of publicly available information regarding backup suppliers, formulation diversity, shipping route exposure, and regulatory compliance of key suppliers further highlights potential vulnerabilities in the supply chain.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the Dutch Medicines Evaluation Board (CBG-MEB) is the primary regulatory authority responsible for the evaluation and supervision of medicines. The key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. The marketing authorization pathway for Indian generics involves obtaining approval from the CBG-MEB, ensuring that imported medicines meet the necessary safety, efficacy, and quality standards before they are made available in the Dutch market.

2Import Licensing & GMP

Import licensing requirements in the Netherlands stipulate that pharmaceutical companies must obtain a wholesale distribution authorization from the CBG-MEB. This authorization ensures that companies comply with Good Manufacturing Practice (GMP) standards, which are recognized by the European Union and the World Health Organization (WHO). Indian exporters seeking to supply Accord Healthcare B.V. must ensure that their manufacturing facilities hold valid EU GMP certificates, as these are essential for the importation and distribution of pharmaceutical products within the Netherlands.

Quality & Labeling

Accord Healthcare B V — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Accord Healthcare B.V.'s focus on oncology and advanced oncology products aligns with the growing demand for cancer treatments in the Netherlands. The importation of finished pharmaceutical formulations, such as temozolomide, fluorouracil, and cisplatin, indicates a strategic emphasis on providing essential cancer therapies. This focus is driven by the increasing prevalence of cancer and the need for accessible, high-quality treatment options within the Dutch healthcare system.

2Sourcing Profile

Accord Healthcare B.V. employs a sourcing strategy that prioritizes high-quality, cost-effective generic medicines, particularly in the oncology therapeutic area. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, makes it a suitable partner for Accord Healthcare B.V. The company's limited engagement with other suppliers suggests a preference for established relationships that offer reliability and consistency in product quality.

3Market Positioning

Based on its product mix, Accord Healthcare B.V. primarily serves the hospital and wholesale distribution segments of the Netherlands market. By importing and distributing essential oncology medications, the company ensures that hospitals and wholesalers have access to critical treatments, thereby supporting the Dutch healthcare system's capacity to provide comprehensive cancer care.

Seller's Guide — How to Become a Supplier to Accord Healthcare B V

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Accord Healthcare B.V.'s supply chain by offering alternative oncology products or formulations that meet the company's quality and regulatory standards. Diversifying the supplier base could enhance Accord Healthcare B.V.'s supply chain resilience and reduce dependency on a single source. However, new suppliers must navigate the stringent regulatory requirements and quality standards set by Dutch authorities to establish a successful partnership.

2Requirements & Qualifications

Indian exporters aiming to supply Accord Healthcare B.V. and the Netherlands market must ensure that their manufacturing facilities hold valid EU GMP certificates. Products must comply with Dutch labeling requirements, including Dutch language labeling and serialization mandates. Additionally, exporters must adhere to the Medicines Act and other relevant Dutch regulations governing pharmaceutical imports to ensure market access.

3How to Approach

Frequently Asked Questions — Accord Healthcare B V

What products does Accord Healthcare B V import from India?

Accord Healthcare B V imports 3 pharmaceutical products across 2 categories. Top imports: Temozolomide ($250.0K), Fluorouracil ($167.3K), Cisplatin ($127.1K).

Who supplies pharmaceuticals to Accord Healthcare B V from India?

Accord Healthcare B V sources from 2 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (97.7% of imports, $2.9M).

What is Accord Healthcare B V's total pharmaceutical import value?

Accord Healthcare B V's total pharmaceutical import value from India is $544.4K, based on 22 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Accord Healthcare B V focus on?

Accord Healthcare B V imports across 2 categories. The largest: Oncology (54.1%), Advanced Oncology (45.9%).

Get Full Accord Healthcare B V Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.